Glenn M Chertow, MD
Nephrology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 17
- 3 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: 052560 · 052819 · 552582 · 552665 · 552682 · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
17 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Chertow’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
17 of 17 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence G84601 · Current
Licensed to practise in California · since 1998 · expires 2028-05-31 · Harvard Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$104,772
Medicare paid this office $104,772 for 264 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Home dialysis services per month (20 years or older) | 15 | $22,293 | $245 |
| Dialysis services, 1 physician visit per month (20 years or older) | 18 | $11,017 | $184 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 14 | $11,002 | $262 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 70 | $10,231 | $70 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 47 | $7,285 | $104 |
See all 13 services
| Home dialysis services per month (20 years or older) | 15 | $22,293 | $245 |
| Dialysis services, 1 physician visit per month (20 years or older) | 18 | $11,017 | $184 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 14 | $11,002 | $262 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 70 | $10,231 | $70 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 47 | $7,285 | $104 |
| Long return visit (40+ min) | 27 | $6,415 | $153 |
| Hemodialysis procedure with physician evaluation | 46 | $6,382 | $63 |
| Dialysis procedure including 1 evaluation | 25 | $5,862 | $76 |
| Return visit (30+ min) | 31 | $3,839 | $120 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 24 | $3,575 | $149 |
| Long return visit (40+ min) | 19 | $3,138 | $112 |
| New patient visit (60+ min) | 15 | $3,029 | $202 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 16 | $1,866 | $117 |
Who their Medicare patients are
264 Original Medicare patients in 2024. Average age 71 · Under 65 22% · 85 and older 11% · Women 42% · Also on Medicaid 36% · Health risk score 5.30. Above the middle of the specialty; the typical nephrology clinician is at 4.01.
Conditions among them: High blood pressure 75% · Chronic kidney disease 75% · Diabetes 60% · Heart failure 57% · Coronary heart disease 52% · Atrial fibrillation 43% · Cancer 26% · COPD 24% · Depression 24% · Stroke 22% · Dementia 20%.
The office billed $466,891, Medicare allowed $136,084 and paid $104,772; for 904 services of 25 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 264 | 904 | 71 | 5.30 | $466,891 | $104,772 |
| 2023 | 235 | 832 | 72 | 4.74 | $419,603 | $91,044 |
| 2022 | 282 | 891 | 72 | 4.65 | $431,545 | $95,862 |
| 2021 | 288 | 1,043 | 70 | 4.48 | $472,435 | $106,080 |
| 2020 | 274 | 1,050 | 67 | 5.43 | $555,290 | $118,632 |
| 2019 | 226 | 719 | 69 | 5.13 | $386,328 | $83,811 |
| 2018 | 243 | 895 | 68 | 4.69 | $370,511 | $78,851 |
| 2017 | 229 | 750 | 67 | 4.85 | $311,537 | $72,738 |
| 2016 | 240 | 957 | 68 | 5.02 | $322,199 | $74,919 |
| 2015 | 229 | 840 | 66 | 5.19 | $322,884 | $75,471 |
| 2014 | 282 | 854 | 64 | 4.99 | $360,145 | $85,226 |
| 2013 | 279 | 1,079 | 65 | 5.19 | $455,873 | $113,163 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 14 services
| Home dialysis services per month (20 years or older) | 12 | $19,830 | $251 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 77 | $11,163 | $72 |
| Dialysis procedure including 1 evaluation | 30 | $8,630 | $81 |
| Dialysis services, 1 physician visit per month (20 years or older) | 12 | $7,500 | $187 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 41 | $7,131 | $110 |
| Hemodialysis procedure with physician evaluation | 40 | $5,709 | $66 |
| Long return visit (40+ min) | 25 | $5,286 | $143 |
| Long return visit (40+ min) | 24 | $5,026 | $129 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 20 | $3,199 | $160 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 19 | $2,272 | $120 |
| Return visit (30+ min) | 22 | $2,256 | $87 |
| Return visit (30+ min) | 13 | $1,507 | $108 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 13 | $903 | $45 |
| Telehealth originating site facility fee | 11 | $247 | $22 |
2022: 14 services
| Home dialysis services per month (20 years or older) | 14 | $22,479 | $253 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 88 | $11,001 | $65 |
| Dialysis services, 1 physician visit per month (20 years or older) | 13 | $8,319 | $189 |
| Hemodialysis procedure with physician evaluation | 56 | $7,924 | $67 |
| Long return visit (40+ min) | 43 | $6,933 | $122 |
| Long return visit (40+ min) | 22 | $5,511 | $157 |
| Dialysis procedure including 1 evaluation | 27 | $5,269 | $81 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 37 | $4,328 | $94 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 22 | $3,863 | $176 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 29 | $3,685 | $123 |
| Return visit (30+ min) | 28 | $2,896 | $85 |
| Return visit (30+ min) | 15 | $1,821 | $114 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 12 | $453 | $35 |
| Telehealth originating site facility fee | 15 | $421 | $22 |
2021: 15 services
| Home dialysis services per month (20 years or older) | 12 | $23,001 | $264 |
| Dialysis services, 1 physician visit per month (20 years or older) | 28 | $12,358 | $184 |
| Dialysis procedure including 1 evaluation | 26 | $10,306 | $82 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 86 | $9,892 | $66 |
| Hemodialysis procedure with physician evaluation | 45 | $7,356 | $67 |
| Long return visit (40+ min) | 32 | $5,821 | $127 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 40 | $5,728 | $95 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 14 | $5,331 | $267 |
| Long return visit (40+ min) | 23 | $4,391 | $163 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 27 | $3,383 | $125 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 15 | $2,776 | $185 |
| Return visit (30+ min) | 27 | $2,731 | $91 |
| Return visit (30+ min) | 12 | $1,415 | $94 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 13 | $495 | $35 |
| Telehealth originating site facility fee | 13 | $346 | $20 |
2020: 17 services
| Home dialysis services per month (20 years or older) | 17 | $23,383 | $207 |
| Dialysis services, 1 physician visit per month (20 years or older) | 27 | $15,380 | $162 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 27 | $12,497 | $223 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 80 | $12,038 | $67 |
| Dialysis procedure including 1 evaluation | 31 | $11,268 | $82 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 47 | $7,588 | $97 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 21 | $7,486 | $267 |
| Hemodialysis procedure with physician evaluation | 47 | $6,840 | $68 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 18 | $3,390 | $188 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 21 | $2,712 | $129 |
| Long return visit (40+ min) | 14 | $2,566 | $122 |
| Return visit (30+ min) | 25 | $1,988 | $64 |
| Return visit (30+ min) | 20 | $1,956 | $85 |
| Telephone medical discussion with physician, 21-30 minutes | 11 | $1,705 | $107 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 15 | $1,408 | $94 |
| Telehealth originating site facility fee | 23 | $749 | $21 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 12 | $436 | $36 |
2019: 13 services
| Dialysis services, 1 physician visit per month (20 years or older) | 29 | $17,964 | $165 |
| Home dialysis services per month (20 years or older) | 15 | $17,618 | $196 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 20 | $8,611 | $205 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 51 | $5,310 | $66 |
| Hemodialysis procedure with physician evaluation | 37 | $4,544 | $66 |
| Long return visit (40+ min) | 25 | $4,096 | $93 |
| Dialysis procedure including 1 evaluation | 12 | $3,729 | $79 |
| Long return visit (40+ min) | 13 | $3,282 | $126 |
| Return visit (30+ min) | 33 | $3,014 | $63 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 16 | $2,547 | $94 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 15 | $1,856 | $124 |
| Return visit (30+ min) | 11 | $1,441 | $85 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 11 | $999 | $91 |
2018: 13 services
| Home dialysis services per month (20 years or older) | 14 | $16,505 | $188 |
| Dialysis services, 1 physician visit per month (20 years or older) | 13 | $12,734 | $168 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 69 | $8,319 | $64 |
| Hemodialysis procedure with physician evaluation | 57 | $7,344 | $64 |
| Dialysis procedure including 1 evaluation | 25 | $4,941 | $76 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 29 | $3,932 | $94 |
| Long return visit (40+ min) | 20 | $3,438 | $98 |
| Long return visit (40+ min) | 14 | $3,290 | $118 |
| Return visit (30+ min) | 27 | $2,484 | $65 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 19 | $2,322 | $122 |
| Return visit (30+ min) | 15 | $2,112 | $88 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 11 | $988 | $90 |
| Short return visit (20+ min) | 15 | $599 | $40 |
2017: 15 services
| Home dialysis services per month (20 years or older) | 14 | $14,949 | $205 |
| Dialysis services, 1 physician visit per month (20 years or older) | 24 | $12,657 | $164 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 58 | $6,543 | $65 |
| Hemodialysis procedure with physician evaluation | 49 | $5,715 | $64 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 29 | $4,394 | $93 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 28 | $3,539 | $122 |
| Dialysis procedure including 1 evaluation | 17 | $3,430 | $78 |
| Return visit (30+ min) | 34 | $2,996 | $64 |
| Long return visit (40+ min) | 22 | $2,981 | $99 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 13 | $2,865 | $205 |
| Long return visit (40+ min) | 11 | $2,569 | $128 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $2,175 | $181 |
| Return visit (30+ min) | 16 | $1,782 | $99 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 11 | $987 | $90 |
| Short return visit (20+ min) | 14 | $639 | $40 |
2016: 13 services
| Home dialysis services per month (20 years or older) | 15 | $13,704 | $208 |
| Dialysis services, 1 physician visit per month (20 years or older) | 25 | $9,744 | $165 |
| Hemodialysis procedure with physician evaluation | 50 | $6,854 | $64 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 56 | $6,109 | $64 |
| Dialysis procedure including 1 evaluation | 22 | $4,613 | $78 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 28 | $3,518 | $93 |
| Return visit (30+ min) | 34 | $2,918 | $66 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 22 | $2,794 | $121 |
| Long return visit (40+ min) | 16 | $2,576 | $95 |
| Return visit (30+ min) | 16 | $2,451 | $88 |
| New patient visit (60+ min) | 12 | $2,162 | $180 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 14 | $1,216 | $87 |
| Short return visit (20+ min) | 15 | $592 | $39 |
2015: 11 services
| Home dialysis services per month (20 years or older) | 11 | $9,431 | $214 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 70 | $8,752 | $64 |
| Dialysis procedure including 1 evaluation | 25 | $7,408 | $78 |
| Hemodialysis procedure with physician evaluation | 55 | $7,158 | $64 |
| Dialysis services, 1 physician visit per month (20 years or older) | 23 | $6,698 | $163 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 39 | $6,610 | $93 |
| Long return visit (40+ min) | 20 | $3,635 | $91 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 28 | $3,415 | $122 |
| Return visit (30+ min) | 27 | $2,874 | $67 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 16 | $1,615 | $90 |
| Short return visit (20+ min) | 11 | $501 | $42 |
2014: 14 services
| Dialysis services, 2-3 physician visits per month (20 years or older) | 28 | $13,911 | $217 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 89 | $10,226 | $63 |
| Dialysis services, 1 physician visit per month (20 years or older) | 42 | $9,921 | $168 |
| Hemodialysis procedure with physician evaluation | 65 | $9,228 | $64 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 56 | $6,932 | $92 |
| Dialysis procedure including 1 evaluation | 20 | $4,752 | $78 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 36 | $4,705 | $121 |
| Long return visit (40+ min) | 17 | $4,394 | $93 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 12 | $4,374 | $257 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 22 | $3,913 | $178 |
| Return visit (30+ min) | 36 | $3,816 | $62 |
| New patient visit (45+ min) | 19 | $1,966 | $103 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 18 | $1,696 | $89 |
| Short return visit (20+ min) | 14 | $637 | $42 |
2013: 15 services
| Dialysis services, 2-3 physician visits per month (20 years or older) | 41 | $28,438 | $215 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 90 | $10,447 | $63 |
| Dialysis services, 1 physician visit per month (20 years or older) | 31 | $9,243 | $168 |
| Hemodialysis procedure with physician evaluation | 54 | $7,361 | $62 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 34 | $6,434 | $174 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 44 | $6,278 | $90 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 12 | $4,846 | $255 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 35 | $4,676 | $117 |
| Long return visit (40+ min) | 29 | $4,458 | $87 |
| Dialysis procedure including 1 evaluation | 16 | $3,890 | $76 |
| Return visit (30+ min) | 46 | $3,794 | $58 |
| New patient visit (60+ min) | 12 | $1,637 | $136 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 17 | $1,398 | $78 |
| Short return visit (20+ min) | 12 | $660 | $44 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 12 | $438 | $34 |
Medicaid work
$4,778 in 2024
Medicaid paid $4,778 for 123 billed services this clinician did in 2024, up to 20 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 93 | $3,107 |
| Hemodialysis procedure with single evaluation by a physician or other qualified health care professional | 30 | $1,672 |
| 2024 | 123 | 2 | 20 | $4,778 |
| 2023 | 164 | 3 | 22 | $8,436 |
| 2022 | 162 | 2 | 23 | $4,986 |
| 2021 | 196 | 4 | 33 | $10,007 |
| 2020 | 232 | 5 | 31 | $21,433 |
| 2019 | 143 | 4 | 22 | $17,488 |
| 2018 | 70 | 2 | 15 | $2,450 |
See the largest Medicaid services in earlier years
2023
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 2-3 face-to-face visits by a physician or other qualified health care professional per month | 14 | $3,697 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 87 | $2,530 |
| Hemodialysis procedure with single evaluation by a physician or other qualified health care professional | 63 | $2,208 |
2022
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 131 | $3,772 |
| Hemodialysis procedure with single evaluation by a physician or other qualified health care professional | 31 | $1,214 |
2021
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 1 face-to-face visit by a physician or other qualified health care professional per month | 33 | $4,869 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 90 | $2,567 |
| Hemodialysis procedure with single evaluation by a physician or other qualified health care professional | 50 | $1,916 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 23 | $655 |
2020
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 31 | $7,445 |
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 2-3 face-to-face visits by a physician or other qualified health care professional per month | 26 | $5,452 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 111 | $3,624 |
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 1 face-to-face visit by a physician or other qualified health care professional per month | 24 | $3,356 |
| Hemodialysis procedure with single evaluation by a physician or other qualified health care professional | 40 | $1,555 |
2019
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 2-3 face-to-face visits by a physician or other qualified health care professional per month | 56 | $10,935 |
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 1 face-to-face visit by a physician or other qualified health care professional per month | 17 | $2,804 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 49 | $2,306 |
| Hemodialysis procedure with single evaluation by a physician or other qualified health care professional | 21 | $1,444 |
2018
| Hemodialysis procedure with single evaluation by a physician or other qualified health care professional | 36 | $1,844 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 34 | $606 |
Drugs they prescribed that Part D paid
$495,955
Pharmacies billed $495,955 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,367) in 2024. At or below the middle of the specialty; the typical nephrology clinician is at 0%.
948 generic and 419 brand-name prescriptions · $495,955 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Farxiga | 209 | $201,721 | $965 |
| Mounjaro | 43 | $44,968 | $1,046 |
| Jardiance | 30 | $35,447 | $1,182 |
| Ozempic | 27 | $25,295 | $937 |
| Trulicity | 21 | $24,625 | $1,173 |
See all 30 drugs
| Farxiga | 209 | $201,721 | $965 |
| Mounjaro | 43 | $44,968 | $1,046 |
| Jardiance | 30 | $35,447 | $1,182 |
| Ozempic | 27 | $25,295 | $937 |
| Trulicity | 21 | $24,625 | $1,173 |
| Sevelamer Carbonate | 37 | $18,957 | $512 |
| Dapagliflozin | 23 | $15,802 | $687 |
| Calcium Acetate | 50 | $6,468 | $129 |
| Losartan | 71 | $883 | $12 |
| Chlorthalidone | 76 | $747 | $10 |
| Carvedilol | 56 | $728 | $13 |
| Valsartan | 27 | $651 | $24 |
| Mycophenolate Mofetil | 14 | $635 | $45 |
| Amlodipine Besylate | 86 | $424 | $5 |
| Spironolactone | 19 | $421 | $22 |
| Nifedipine Er | 15 | $395 | $26 |
| Hydralazine | 12 | $365 | $30 |
| Furosemide | 33 | $290 | $9 |
| Telmisartan | 13 | $282 | $22 |
| Ramipril | 24 | $268 | $11 |
| Lactulose | 16 | $250 | $16 |
| Allopurinol | 22 | $227 | $10 |
| Tamsulosin | 17 | $194 | $11 |
| Doxazosin Mesylate | 12 | $182 | $15 |
| Calcitriol | 17 | $171 | $10 |
| Levothyroxine | 14 | $164 | $12 |
| Lisinopril | 15 | $156 | $10 |
| Atorvastatin | 36 | $150 | $4 |
| Prednisone | 16 | $119 | $7 |
| Metoprolol | 12 | $89 | $7 |
Year by year
| 2024 | 1,367 | 176 | 0% (0) | 31% | $495,955 |
| 2023 | 1,262 | 165 | None | 38% | $544,221 |
| 2022 | 1,051 | 145 | 0% (0) | None | $384,722 |
| 2021 | 1,130 | 142 | 2% (25) | None | $273,383 |
| 2020 | 1,005 | 114 | 3% (32) | 18% | $170,412 |
| 2019 | 1,290 | 108 | 2% (30) | 27% | $234,750 |
| 2018 | 1,314 | 100 | 3% (34) | None | $307,535 |
| 2017 | 1,340 | 96 | 3% (38) | 25% | $324,227 |
| 2016 | 1,227 | 100 | 3% (41) | None | $293,035 |
| 2015 | 939 | 83 | 3% (28) | 32% | $278,538 |
| 2014 | 944 | 72 | 3% (24) | None | $206,426 |
| 2013 | 964 | 79 | 5% (51) | 32% | $164,470 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 23 drugs
| Farxiga | 290 | $272,086 | $938 |
| Trulicity | 50 | $54,987 | $1,100 |
| Eliquis | 25 | $29,369 | $1,175 |
| Jardiance | 34 | $27,001 | $794 |
| Lokelma | 14 | $15,987 | $1,142 |
| Sevelamer Carbonate | 21 | $9,158 | $436 |
| Calcium Acetate | 47 | $7,076 | $151 |
| Eplerenone | 16 | $1,442 | $90 |
| Torsemide | 14 | $1,380 | $99 |
| Losartan | 61 | $1,355 | $22 |
| Carvedilol | 86 | $1,320 | $15 |
| Chlorthalidone | 61 | $1,132 | $19 |
| Amlodipine Besylate | 63 | $915 | $15 |
| Furosemide | 45 | $864 | $19 |
| Lactulose | 14 | $685 | $49 |
| Tamsulosin | 25 | $614 | $25 |
| Ramipril | 26 | $489 | $19 |
| Atorvastatin | 32 | $433 | $14 |
| Valsartan | 13 | $381 | $29 |
| Allopurinol | 30 | $380 | $13 |
| Lisinopril | 20 | $329 | $16 |
| Gabapentin | 18 | $144 | $8 |
| Spironolactone | 20 | $84 | $4 |
2022: 23 drugs
| Farxiga | 208 | $184,315 | $886 |
| Prezcobix | 13 | $31,433 | $2,418 |
| Tivicay | 13 | $28,243 | $2,173 |
| Sevelamer Carbonate | 18 | $14,328 | $796 |
| Jardiance | 20 | $12,968 | $648 |
| Lokelma | 12 | $9,733 | $811 |
| Eliquis | 15 | $9,333 | $622 |
| Calcium Acetate | 43 | $6,448 | $150 |
| Retacrit | 17 | $3,077 | $181 |
| Torsemide | 17 | $1,018 | $60 |
| Losartan | 57 | $839 | $15 |
| Chlorthalidone | 40 | $766 | $19 |
| Carvedilol | 61 | $611 | $10 |
| Atorvastatin | 35 | $541 | $15 |
| Lisinopril | 28 | $482 | $17 |
| Amlodipine Besylate | 56 | $421 | $8 |
| Ramipril | 24 | $351 | $15 |
| Allopurinol | 17 | $319 | $19 |
| Tamsulosin | 15 | $292 | $19 |
| Furosemide | 24 | $280 | $12 |
| Spironolactone | 21 | $139 | $7 |
| Gabapentin | 23 | $135 | $6 |
| Metoprolol | 13 | $38 | $3 |
2021: 26 drugs
| Farxiga | 119 | $90,376 | $759 |
| Eliquis | 47 | $25,209 | $536 |
| Cinacalcet | 14 | $12,029 | $859 |
| Sevelamer Carbonate | 33 | $11,819 | $358 |
| Calcium Acetate | 37 | $3,925 | $106 |
| Fentanyl | 15 | $1,487 | $99 |
| Losartan | 75 | $1,226 | $16 |
| Cyclosporine Modified | 13 | $1,119 | $86 |
| Torsemide | 13 | $1,118 | $86 |
| Chlorthalidone | 48 | $911 | $19 |
| Carvedilol | 73 | $806 | $11 |
| Calcitriol | 20 | $667 | $33 |
| Valsartan | 11 | $561 | $51 |
| Amlodipine Besylate | 44 | $465 | $11 |
| Famotidine | 21 | $337 | $16 |
| Lisinopril | 41 | $331 | $8 |
| Allopurinol | 19 | $319 | $17 |
| Ramipril | 18 | $292 | $16 |
| Tamsulosin | 16 | $265 | $17 |
| Atorvastatin | 21 | $253 | $12 |
| Metoprolol | 13 | $197 | $15 |
| Furosemide | 23 | $132 | $6 |
| Gabapentin | 20 | $126 | $6 |
| Metformin Hcl Er | 17 | $112 | $7 |
| Metoprolol | 24 | $79 | $3 |
| Glipizide | 14 | $57 | $4 |
2020: 25 drugs
| Renvela | 21 | $46,421 | $2,211 |
| Cinacalcet | 31 | $25,832 | $833 |
| Eliquis | 31 | $15,357 | $495 |
| Sevelamer Carbonate | 42 | $11,732 | $279 |
| Prosol | 25 | $7,906 | $316 |
| Calcium Acetate | 39 | $4,439 | $114 |
| Torsemide | 19 | $2,085 | $110 |
| Oxycodone | 12 | $1,977 | $165 |
| Cyclosporine Modified | 11 | $1,538 | $140 |
| Chlorthalidone | 46 | $1,246 | $27 |
| Losartan | 65 | $1,210 | $19 |
| Lactulose | 16 | $831 | $52 |
| Carvedilol | 72 | $652 | $9 |
| Allopurinol | 32 | $433 | $14 |
| Famotidine | 19 | $383 | $20 |
| Atorvastatin | 27 | $340 | $13 |
| Metoprolol | 14 | $311 | $22 |
| Amlodipine Besylate | 42 | $302 | $7 |
| Levothyroxine | 13 | $297 | $23 |
| Tamsulosin | 16 | $214 | $13 |
| Ramipril | 11 | $198 | $18 |
| Lisinopril | 21 | $171 | $8 |
| Furosemide | 24 | $154 | $6 |
| Metoprolol | 28 | $97 | $3 |
| Gabapentin | 23 | $78 | $3 |
2019: 29 drugs
| Renvela | 25 | $36,149 | $1,446 |
| Cinacalcet | 14 | $28,115 | $2,008 |
| Sevelamer Carbonate | 40 | $22,764 | $569 |
| Prosol | 82 | $18,576 | $227 |
| Auryxia | 23 | $17,389 | $756 |
| Eliquis | 17 | $7,695 | $453 |
| Intralipid | 53 | $6,840 | $129 |
| Calcium Acetate | 39 | $3,580 | $92 |
| Clinisol | 21 | $3,186 | $152 |
| Chlorthalidone | 90 | $2,210 | $25 |
| Dextrose in Water | 53 | $1,017 | $19 |
| Lactulose | 19 | $1,010 | $53 |
| Losartan | 69 | $966 | $14 |
| Carvedilol | 65 | $751 | $12 |
| Allopurinol | 52 | $688 | $13 |
| Torsemide | 20 | $597 | $30 |
| Metoprolol | 16 | $586 | $37 |
| Ramipril | 20 | $502 | $25 |
| Atorvastatin | 37 | $469 | $13 |
| Amlodipine Besylate | 60 | $464 | $8 |
| Calcitriol | 16 | $384 | $24 |
| Levothyroxine | 21 | $370 | $18 |
| Furosemide | 41 | $365 | $9 |
| Famotidine | 20 | $174 | $9 |
| Hydrocodone-Acetaminophen | 16 | $173 | $11 |
| Lisinopril | 13 | $165 | $13 |
| Omeprazole | 19 | $106 | $6 |
| Gabapentin | 16 | $104 | $6 |
| Metoprolol | 24 | $76 | $3 |
2018: 32 drugs
| Renvela | 57 | $80,827 | $1,418 |
| Sensipar | 36 | $57,203 | $1,589 |
| Sevelamer Carbonate | 35 | $35,266 | $1,008 |
| Auryxia | 16 | $17,977 | $1,124 |
| Prosol | 41 | $8,643 | $211 |
| Intralipid | 41 | $5,281 | $129 |
| Calcium Acetate | 44 | $4,483 | $102 |
| Clinisol | 15 | $2,283 | $152 |
| Chlorthalidone | 70 | $1,818 | $26 |
| Metolazone | 14 | $913 | $65 |
| Losartan | 85 | $893 | $11 |
| Omega-3 Acid Ethyl Esters | 12 | $741 | $62 |
| Carvedilol | 73 | $735 | $10 |
| Fentanyl | 11 | $623 | $57 |
| Torsemide | 31 | $618 | $20 |
| Allopurinol | 55 | $586 | $11 |
| Amlodipine Besylate | 69 | $414 | $6 |
| Atorvastatin | 20 | $345 | $17 |
| Labetalol | 16 | $327 | $20 |
| Furosemide | 52 | $320 | $6 |
| Tamsulosin | 11 | $251 | $23 |
| Levothyroxine | 13 | $203 | $16 |
| Famotidine | 33 | $193 | $6 |
| Lisinopril | 29 | $180 | $6 |
| Dextrose in Water | 41 | $176 | $4 |
| Ramipril | 14 | $165 | $12 |
| Hydrocodone-Acetaminophen | 16 | $162 | $10 |
| Ondansetron | 13 | $95 | $7 |
| Omeprazole | 13 | $95 | $7 |
| Gabapentin | 14 | $85 | $6 |
| Sulfamethoxazole-Trimethoprim | 18 | $48 | $3 |
| Montelukast | 12 | $42 | $4 |
2017: 34 drugs
| Sensipar | 117 | $119,576 | $1,022 |
| Renvela | 70 | $94,893 | $1,356 |
| Xifaxan | 12 | $24,023 | $2,002 |
| Clinisol | 92 | $14,114 | $153 |
| Uloric | 14 | $5,062 | $362 |
| Calcium Acetate | 44 | $4,258 | $97 |
| Torsemide | 49 | $1,109 | $23 |
| Hydroxychloroquine Sulfate | 11 | $994 | $90 |
| Isradipine | 12 | $993 | $83 |
| Fentanyl | 13 | $855 | $66 |
| Labetalol | 22 | $840 | $38 |
| Carvedilol | 93 | $796 | $9 |
| Chlorthalidone | 34 | $790 | $23 |
| Metolazone | 22 | $770 | $35 |
| Allopurinol | 43 | $763 | $18 |
| Omega-3 Acid Ethyl Esters | 12 | $727 | $61 |
| Losartan | 54 | $531 | $10 |
| Amlodipine Besylate | 100 | $475 | $5 |
| Furosemide | 66 | $458 | $7 |
| Bupropion | 11 | $385 | $35 |
| Tamsulosin | 17 | $314 | $18 |
| Atorvastatin | 24 | $311 | $13 |
| Levothyroxine | 20 | $298 | $15 |
| Calcitriol | 11 | $251 | $23 |
| Valsartan | 11 | $220 | $20 |
| Hydrocodone-Acetaminophen | 20 | $212 | $11 |
| Metoprolol | 11 | $175 | $16 |
| Lisinopril | 31 | $161 | $5 |
| Famotidine | 25 | $116 | $5 |
| Pantoprazole | 12 | $100 | $8 |
| Doxazosin Mesylate | 11 | $96 | $9 |
| Gabapentin | 13 | $77 | $6 |
| Montelukast | 13 | $76 | $6 |
| Trazodone | 13 | $33 | $3 |
2016: 33 drugs
| Renvela | 89 | $122,615 | $1,378 |
| Sensipar | 80 | $91,054 | $1,138 |
| Clinisol | 60 | $9,044 | $151 |
| Uloric | 16 | $6,029 | $377 |
| Calcium Acetate | 34 | $3,386 | $100 |
| Plavix | 12 | $2,550 | $213 |
| Clonidine | 18 | $2,350 | $131 |
| Labetalol | 24 | $1,347 | $56 |
| Omega-3 Acid Ethyl Esters | 12 | $852 | $71 |
| Fentanyl | 13 | $764 | $59 |
| Chlorthalidone | 25 | $662 | $26 |
| Torsemide | 53 | $659 | $12 |
| Isradipine | 11 | $608 | $55 |
| Nifedipine Er | 11 | $510 | $46 |
| Amlodipine Besylate | 81 | $474 | $6 |
| Allopurinol | 31 | $412 | $13 |
| Carvedilol | 66 | $365 | $6 |
| Furosemide | 56 | $356 | $6 |
| Levothyroxine | 28 | $343 | $12 |
| Ramipril | 20 | $326 | $16 |
| Tamsulosin | 17 | $319 | $19 |
| Metoprolol | 20 | $295 | $15 |
| Losartan | 41 | $280 | $7 |
| Hydrocodone-Acetaminophen | 19 | $273 | $14 |
| Calcitriol | 11 | $263 | $24 |
| Bupropion | 12 | $262 | $22 |
| Atorvastatin | 24 | $196 | $8 |
| Clonidine | 13 | $173 | $13 |
| Pantoprazole | 17 | $153 | $9 |
| Montelukast | 12 | $149 | $12 |
| Lisinopril | 37 | $147 | $4 |
| Doxazosin Mesylate | 11 | $111 | $10 |
| Trazodone | 18 | $41 | $2 |
2015: 24 drugs
| Renvela | 97 | $125,683 | $1,296 |
| Sensipar | 101 | $118,820 | $1,176 |
| Clinisol | 49 | $9,167 | $187 |
| Calcium Acetate | 23 | $3,355 | $146 |
| Plavix | 14 | $2,975 | $213 |
| Omega-3 Acid Ethyl Esters | 11 | $1,124 | $102 |
| Fentanyl | 11 | $837 | $76 |
| Metoprolol | 14 | $580 | $41 |
| Chlorthalidone | 18 | $464 | $26 |
| Torsemide | 31 | $423 | $14 |
| Amlodipine Besylate | 90 | $329 | $4 |
| Acyclovir | 12 | $268 | $22 |
| Furosemide | 45 | $245 | $5 |
| Atorvastatin | 32 | $244 | $8 |
| Montelukast | 14 | $232 | $17 |
| Armour Thyroid | 12 | $182 | $15 |
| Lisinopril | 31 | $180 | $6 |
| Levothyroxine | 15 | $170 | $11 |
| Carvedilol | 34 | $143 | $4 |
| Clonidine | 12 | $122 | $10 |
| Allopurinol | 11 | $109 | $10 |
| Omeprazole | 11 | $94 | $9 |
| Escitalopram | 15 | $69 | $5 |
| Losartan | 19 | $67 | $4 |
2014: 23 drugs
| Sensipar | 88 | $77,194 | $877 |
| Renvela | 66 | $74,657 | $1,131 |
| Clinisol | 34 | $5,556 | $163 |
| Calcium Acetate | 27 | $5,143 | $190 |
| Paricalcitol | 11 | $3,755 | $341 |
| Plavix | 12 | $2,550 | $213 |
| Lovaza | 13 | $2,264 | $174 |
| Prosol | 12 | $1,805 | $150 |
| Intralipid | 16 | $1,306 | $82 |
| Metoprolol | 38 | $1,058 | $28 |
| Torsemide | 27 | $787 | $29 |
| Ramipril | 31 | $589 | $19 |
| Chlorthalidone | 24 | $441 | $18 |
| Atorvastatin | 30 | $386 | $13 |
| Amlodipine Besylate | 57 | $286 | $5 |
| Pravastatin | 13 | $286 | $22 |
| Lisinopril | 32 | $265 | $8 |
| Carvedilol | 40 | $209 | $5 |
| Furosemide | 30 | $148 | $5 |
| Omeprazole | 19 | $127 | $7 |
| Gabapentin | 11 | $94 | $9 |
| Clonidine | 14 | $67 | $5 |
| Fluoxetine | 13 | $65 | $5 |
2013: 30 drugs
| Renvela | 84 | $69,872 | $832 |
| Sensipar | 48 | $41,092 | $856 |
| Calcium Acetate | 35 | $6,134 | $175 |
| Intralipid | 51 | $5,339 | $105 |
| Clinisol | 25 | $3,416 | $137 |
| Lipitor | 14 | $2,702 | $193 |
| Lovaza | 11 | $1,648 | $150 |
| Labetalol | 18 | $942 | $52 |
| Metoprolol | 20 | $674 | $34 |
| Ramipril | 41 | $556 | $14 |
| Amlodipine Besylate | 44 | $251 | $6 |
| Gabapentin | 27 | $241 | $9 |
| Carvedilol | 31 | $230 | $7 |
| Atorvastatin | 15 | $228 | $15 |
| Furosemide | 38 | $226 | $6 |
| Omeprazole | 14 | $192 | $14 |
| Methadone | 13 | $180 | $14 |
| Simvastatin | 12 | $169 | $14 |
| Lisinopril | 22 | $167 | $8 |
| Hydrocodone-Acetaminophen | 19 | $163 | $9 |
| Chlorthalidone | 11 | $153 | $14 |
| Clonidine | 23 | $153 | $7 |
| Calcitriol | 14 | $128 | $9 |
| Levothyroxine | 12 | $126 | $11 |
| Pravastatin | 13 | $118 | $9 |
| Prednisone | 17 | $113 | $7 |
| Losartan | 12 | $76 | $6 |
| Fluoxetine | 13 | $76 | $6 |
| Amitriptyline | 13 | $69 | $5 |
| Armour Thyroid | 11 | $59 | $5 |
Money from drug and device companies
$322,959 in 2025
| 2025 | 12 | 83 | $312,917 | $322,959 |
| 2024 | 15 | 66 | $273,073 | $276,263 |
| 2023 | 11 | 36 | $343,519 | $344,512 |
| 2022 | 12 | 52 | $442,541 | $442,923 |
| 2021 | 11 | 35 | $385,411 | $385,411 |
| 2020 | 9 | 21 | $67,313 | $67,313 |
| 2019 | 9 | 62 | $165,608 | $182,198 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Akebia Therapeutics | Vafseo | $89,878 | 13 payments
|
| Vertex Pharmaceuticals | None | $82,483 | 17 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $77,441 | 24 payments
|
| AstraZeneca UK | Farxiga | $34,026 | 11 payments
|
| Travere Therapeutics | None | $16,000 | 2 payments
|
| CSL Behring | None | $10,390 | 8 payments
|
See all 83 published payments
| GlaxoSmithKline | Consulting · 2025-12-24 | None | $5,000 |
| AstraZeneca Pharmaceuticals LP | Consulting · 2025-12-23 | Farxiga | $1,050 |
| AstraZeneca UK | Consulting · 2025-12-18 | Farxiga | $4,000 |
| Akebia Therapeutics | Consulting · 2025-12-18 | Vafseo | $8,940 |
| Vertex Pharmaceuticals | Meals · 2025-12-17 | None | $104 |
| Vertex Pharmaceuticals | Travel · 2025-12-17 | None | $155 |
| Vertex Pharmaceuticals | Travel · 2025-12-17 | None | $362 |
| Vertex Pharmaceuticals | Travel · 2025-12-17 | None | $541 |
| AstraZeneca Pharmaceuticals LP | Consulting · 2025-12-11 | Farxiga | $1,400 |
| AstraZeneca Pharmaceuticals LP | Consulting · 2025-12-10 | Farxiga | $700 |
| AstraZeneca Pharmaceuticals LP | Consulting · 2025-12-10 | Farxiga | $1,400 |
| AstraZeneca Pharmaceuticals LP | Consulting · 2025-12-05 | Farxiga | $700 |
| AstraZeneca Pharmaceuticals LP | Consulting · 2025-12-04 | Farxiga | $1,750 |
| GlaxoSmithKline | Consulting · 2025-12-02 | None | $1,000 |
| Vertex Pharmaceuticals | Meals · 2025-11-06 | None | $28 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-11-06 | None | $120 |
| AstraZeneca UK | Meals · 2025-11-05 | None | $76 |
| Akebia Therapeutics | Meals · 2025-11-05 | Auryxia | $123 |
| Ardelyx | Meals · 2025-11-05 | Ibsrela | $32 |
| AstraZeneca Pharmaceuticals LP | Consulting · 2025-10-29 | None | $12,600 |
| AstraZeneca UK | Consulting · 2025-10-24 | Farxiga | $10,400 |
| Vertex Pharmaceuticals | Consulting · 2025-10-22 | None | $28,800 |
| AstraZeneca Pharmaceuticals LP | Consulting · 2025-10-16 | None | $11,200 |
| AstraZeneca UK | Consulting · 2025-09-17 | Farxiga | $4,800 |
| AstraZeneca Pharmaceuticals LP | Consulting · 2025-09-11 | None | $9,800 |
| AstraZeneca Pharmaceuticals LP | Consulting · 2025-09-11 | None | $1,400 |
| Travere Therapeutics | Consulting · 2025-09-02 | None | $10,000 |
| AstraZeneca UK | Consulting · 2025-08-27 | Farxiga | $1,500 |
| AstraZeneca Pharmaceuticals LP | Consulting · 2025-08-15 | Farxiga | $1,400 |
| Alnylam Pharmaceuticals | Consulting · 2025-08-14 | None | $4,900 |
| Akebia Therapeutics | Consulting · 2025-08-06 | Vafseo | $11,548 |
| AstraZeneca Pharmaceuticals LP | Consulting · 2025-08-01 | None | $2,300 |
| Travere Therapeutics | Consulting · 2025-07-29 | None | $6,000 |
| AstraZeneca Pharmaceuticals LP | Consulting · 2025-07-23 | None | $1,400 |
| AstraZeneca UK | Consulting · 2025-07-21 | None | $500 |
| AstraZeneca Pharmaceuticals LP | Consulting · 2025-07-18 | Farxiga | $1,400 |
| AstraZeneca Pharmaceuticals LP | Consulting · 2025-07-18 | None | $3,500 |
| Vertex Pharmaceuticals | Consulting · 2025-07-16 | None | $7,650 |
| AstraZeneca Pharmaceuticals LP | Consulting · 2025-07-15 | None | $9,100 |
| AstraZeneca UK | Consulting · 2025-07-14 | Farxiga | $575 |
| CSL Behring | Consulting · 2025-07-14 | None | $542 |
| CSL Behring | Consulting · 2025-07-14 | None | $542 |
| GlaxoSmithKline | Consulting · 2025-07-11 | None | $1,000 |
| AstraZeneca Pharmaceuticals LP | Consulting · 2025-07-09 | None | $2,100 |
| CSL Behring | Consulting · 2025-06-27 | None | $2,892 |
| Insmed | Consulting · 2025-06-24 | None | $580 |
| Novo Nordisk | Meals · 2025-06-23 | Ozempic | $108 |
| AstraZeneca Pharmaceuticals LP | Travel · 2025-06-06 | None | $9 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-06-06 | None | $57 |
| Vertex Pharmaceuticals | Meals · 2025-06-05 | None | $69 |
| AstraZeneca UK | Consulting · 2025-06-03 | Farxiga | $575 |
| Akebia Therapeutics | Consulting · 2025-05-28 | Vafseo | $44,328 |
| AstraZeneca UK | Consulting · 2025-05-22 | Farxiga | $5,600 |
| AstraZeneca UK | Consulting · 2025-05-22 | Lokelma | $1,000 |
| AstraZeneca Pharmaceuticals LP | Consulting · 2025-05-22 | None | $5,250 |
| Vertex Pharmaceuticals | Consulting · 2025-05-21 | None | $9,000 |
| AstraZeneca UK | Consulting · 2025-05-15 | Lokelma | $5,000 |
| AstraZeneca Pharmaceuticals LP | Consulting · 2025-05-09 | None | $1,725 |
| AstraZeneca Pharmaceuticals LP | Consulting · 2025-04-15 | Farxiga | $2,100 |
| Vertex Pharmaceuticals | Travel · 2025-04-09 | None | $262 |
| Vertex Pharmaceuticals | Travel · 2025-04-09 | None | $68 |
| Vertex Pharmaceuticals | Meals · 2025-04-09 | None | $21 |
| Vertex Pharmaceuticals | Consulting · 2025-04-09 | None | $13,500 |
| Vertex Pharmaceuticals | Travel · 2025-03-19 | None | $255 |
| Vertex Pharmaceuticals | Meals · 2025-03-19 | None | $28 |
| Vertex Pharmaceuticals | Meals · 2025-03-19 | None | $42 |
| AstraZeneca Pharmaceuticals LP | Consulting · 2025-03-06 | None | $2,300 |
| Vertex Pharmaceuticals | Consulting · 2025-03-05 | None | $21,600 |
| AstraZeneca Pharmaceuticals LP | Consulting · 2025-01-23 | None | $2,800 |
| CSL Behring | Travel · 2025-01-22 | None | $386 |
| CSL Behring | Travel · 2025-01-22 | None | $65 |
| CSL Behring | Meals · 2025-01-21 | None | $21 |
| Akebia Therapeutics | Consulting · 2025-01-21 | Vafseo | $2,500 |
| Akebia Therapeutics | Consulting · 2025-01-21 | Vafseo | $16,800 |
| Akebia Therapeutics | Travel · 2025-01-21 | Vafseo | $388 |
| Akebia Therapeutics | Travel · 2025-01-21 | Vafseo | $582 |
| Akebia Therapeutics | Travel · 2025-01-21 | Vafseo | $62 |
| Akebia Therapeutics | Travel · 2025-01-21 | Vafseo | $51 |
| Akebia Therapeutics | Travel · 2025-01-21 | Vafseo | $42 |
| Akebia Therapeutics | Travel · 2025-01-21 | Vafseo | $46 |
| CSL Behring | Travel · 2025-01-20 | None | $5,877 |
| CSL Behring | Travel · 2025-01-20 | None | $65 |
| Akebia Therapeutics | Consulting · 2025-01-08 | Vafseo | $4,470 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $276,263
| AstraZeneca Pharmaceuticals LP | None | $110,905 | 23 payments
|
| Vertex Pharmaceuticals | None | $70,763 | 10 payments
|
| Outset Medical | None | $46,500 | 2 payments
|
| Ardelyx | Xphozah 30 Mg | $25,200 | 10 payments
|
| Akebia Therapeutics | Vafseo | $6,268 | 4 payments
|
| AstraZeneca UK | Farxiga | $6,250 | 5 payments
|
| ZOLL Medical | Defibrillator | $3,017 | 3 payments
|
| Alexion Pharmaceuticals | None | $2,010 | 1 payment
|
| AstraZeneca AB | None | $1,725 | 1 payment
|
| Baxter Healthcare | Renal - Theranova | $1,240 | 1 payment
|
| Insmed | None | $1,117 | 1 payment
|
| BeiGene USA | None | $1,000 | 1 payment
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $146 | 1 payment
|
| Novartis Pharmaceuticals | Fabhalta | $65 | 2 payments
|
| Aurinia Pharma U.S. | Lupkynis | $58 | 1 payment
|
2023: $344,512
| Outset Medical | None | $159,884 | 2 payments
|
| Vertex Pharmaceuticals | None | $64,345 | 7 payments
|
| Ardelyx | Xphozah 30 Mg | $47,900 | 5 payments
|
| AstraZeneca Pharmaceuticals LP | None | $38,625 | 5 payments
|
| AstraZeneca UK | None | $20,250 | 8 payments
|
| Akebia Therapeutics | None | $11,500 | 2 payments
|
| Novo Nordisk AS | None | $1,575 | 1 payment
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $183 | 3 payments
|
| Amgen | Tavneos | $122 | 1 payment
|
| Alexion Pharmaceuticals | Ultomiris | $100 | 1 payment
|
| Travere Therapeutics | None | $28 | 1 payment
|
2022: $442,923
| Outset Medical | None | $145,671 | 1 payment
|
| Ardelyx | None | $120,600 | 11 payments
|
| AstraZeneca Pharmaceuticals LP | Lokelma | $63,250 | 12 payments
|
| Akebia Therapeutics | None | $46,750 | 7 payments
|
| Vertex Pharmaceuticals | None | $21,433 | 4 payments
|
| Gilead Sciences | None | $17,750 | 4 payments
|
| GlaxoSmithKline | None | $11,067 | 2 payments
|
| AstraZeneca UK | Farxiga | $9,375 | 4 payments
|
| AstraZeneca AB | None | $2,500 | 1 payment
|
| Travere Therapeutics | None | $2,000 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Kerendia | $1,870 | 3 payments
|
| Amgen | Tavneos | $656 | 2 payments
|
2021: $385,411
| Outset Medical | None | $289,961 | 10 payments
|
| Akebia Therapeutics | Auryxia | $56,610 | 7 payments
|
| Gilead Sciences | None | $13,220 | 5 payments
|
| AstraZeneca AB | Farxiga | $7,000 | 2 payments
|
| Otsuka Pharmaceutical Development & Commercialization | None | $5,440 | 1 payment
|
| Vertex Pharmaceuticals | None | $5,118 | 4 payments
|
| CSL Behring | None | $3,026 | 1 payment
|
| Travere Therapeutics | None | $2,000 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | None | $1,250 | 1 payment
|
| Alnylam Pharmaceuticals | None | $960 | 1 payment
|
| Lilly USA | Jardiance | $825 | 1 payment
|
2020: $67,313
| Akebia Therapeutics | Auryxia | $28,500 | 6 payments
|
| Gilead Sciences | None | $11,500 | 2 payments
|
| AstraZeneca AB | Farxiga | $9,000 | 4 payments
|
| Vertex Pharmaceuticals | None | $6,240 | 3 payments
|
| AstraZeneca Pharmaceuticals LP | None | $4,279 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Non-Covered | $3,360 | 2 payments
|
| AstraZeneca UK | None | $3,112 | 1 payment
|
| Otsuka Pharmaceutical Development & Commercialization | None | $1,005 | 1 payment
|
| Vifor (International) | None | $317 | 1 payment
|
2019: $182,198
| Akebia Therapeutics | Auryxia | $72,307 | 9 payments
|
| Gilead Sciences | None | $51,159 | 11 payments
|
| AstraZeneca AB | Farxiga | $20,250 | 2 payments
|
| Bayer HealthCare Pharmaceuticals | Non-Covered | $20,076 | 14 payments
|
| Baxter Healthcare | Renal - Theranova | $13,244 | 8 payments
|
| AstraZeneca UK | Lokelma | $2,190 | 4 payments
|
| Vertex Pharmaceuticals | None | $1,821 | 11 payments
|
| Kyowa Hakko Kirin Co. | None | $1,101 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | None | $49 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Amgen Inc. · Evolve · 2019 | Their institution | $200,000 |
| Bayer Healthcare Pharmaceuticals Inc. · Protocol Number 21177 (Study), Bay94-8862 Finerenone · 2025 | This clinician | $38,950 |
| Bayer Healthcare Pharmaceuticals Inc. · Bayer 19920-20186 Finerenone Study · 2025 | This clinician | $27,000 |
| Janssen Research & Development, LLC · Credence Study Investigating the Potential for Canagliflozin To Improve Renal Outcomes in Diabetes Patients · 2019 | Their institution | $26,671 |
| Amgen Inc. · Ph3 Kai 4169 Secondary Hpt 2 · 2019 | This clinician | $12,699 |
| Amgen Inc. · Etelcalcetide-Induced Changes in Serum Calcium and Bone Turnover Markers and the Severity of Second · 2020 | This clinician | $6,193 |
| Amgen Inc. · Parsabiv · 2019 | This clinician | $5,022 |
| Amgen Inc. · Fibroblast Growth Factor 23 As A Risk Factor for Cardiovascular Events and Mortality in Patients in · 2020 | This clinician | $4,602 |
| Bayer Healthcare Pharmaceuticals Inc. · Protocol Number 21177 Study Bay94-8862 · 2025 | This clinician | $4,275 |
| Amgen Inc. · Ph3 Kai 4169 Secondary Hpt Ole · 2019 | This clinician | $3,072 |
| Amgen Inc. · Ph3 Kai 4169 Secondary Hpt 1 · 2019 | This clinician | $2,042 |
| Gilead Sciences, Inc. · A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects With Moderate To Advanced Diabetic Kidney Disease · 2019 | This clinician | $890 |
| AKEBIA THERAPEUTICS INC · Akb-6548-Ci-0014 · 2019 | Their institution | $420 |
| Amgen Inc. · Evolve · 2019 | This clinician | $33 |
| Amgen Inc. · Ph3 Switch Study: Converting From Cinacalcet To Amg 416 · 2020 | This clinician | $18 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1407823875
- Licence
- CA G84601California G84601: Current · expires 2028-05-31
- Trained
- Harvard Medical School, 1989
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00G846010
- Taxonomy
- Federal specialty code 207RN0300X (207RN0300X); Internal medicine (207R00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2006-03-03
- NPI last updated
- 2024-04-18
- NPI record certified
- 2024-04-18
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 774 11th Ave, San Francisco, CA, 94118